查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1487557

腫瘤學市場的伴隨診斷測試（檢測技術：蛋白質檢測、DNA 檢測等；以及生物標記：EGFR、KRAS、HER2、BRAF V600E 等）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2024- 2034

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 232 Pages | 商品交期: 2-10個工作天內

價格

腫瘤學市場的伴隨診斷測試 - 報告範圍

TMR 關於全球腫瘤學伴隨診斷測試市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。 2034 年腫瘤學市場診斷測試，以2024 年為基準年，2034 年為預測年。該報告也提供了2024年至2034年全球腫瘤學伴隨診斷測試市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解腫瘤市場的伴隨診斷測試。

市場概況
2023年市場價值 61 億美元
2034 年市場價值 170 億美元
複合年成長率 9.5%

該報告深入研究了腫瘤市場全球伴隨診斷測試的競爭格局。腫瘤學市場全球伴隨診斷測試中的主要參與者已經確定，並且每位參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球腫瘤學伴隨診斷測試市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020 - 2034 年全球市場分析與預測

第 5 章：主要見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：透過檢測技術

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按檢測技術，2020 - 2034
    • 蛋白質檢測
      • 免疫組織化學
    • DNA檢測
      • 聚合酶鍊式反應 (PCR)
      • 新一代定序 (NGS)
      • 原位雜合技術
    • 其他
  • 市場吸引力：透過檢測技術

第 7 章：全球市場分析與預測：按 Biomarker

  • 簡介和定義
  • 主要發現/進展
  • 市值預測：依 Biomarker 分類，2020 - 2034 年
    • 表皮生長因子受體
    • 克拉斯
    • HER2
    • 布拉夫V600E
    • 其他
    • 7.4 市場吸引力：依生物標記

第 8 章：全球市場分析與預測：按癌症類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按癌症類型，2020 - 2034
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 肝癌
    • 黑色素瘤
    • 其他
  • 市場吸引力：按癌症類型

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020 - 2034
    • 醫院
    • 專科診所
    • 診斷實驗室
    • 其他
  • 市場吸引力：按最終用戶分類

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020 - 2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Abbott
    • F. Hoffmann-LA Roche AG
    • Genomic Health, Inc.
    • QIAGEN
    • Agilent Technologies, Inc.
    • AGENDIA NV
    • bioMerieux SA
    • Illumina, Inc.
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • BioGenex
Product Code: TMRGL4684

Companion Diagnostic Tests in Oncology Market - Scope of Report

TMR's report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.

Market Snapshot
Market Value in 2023US$ 6.1 Bn
Market Value in 2034US$ 17 Bn
CAGR9.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.

The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.

Key Questions Answered in Global companion diagnostic tests in oncology Market Report:

  • What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
  • What are the opportunities in the global companion diagnostic tests in oncology market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Companion Diagnostic Tests in Oncology Market - Research Objectives and Research Approach

The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 6.3.1. Protein Detection
      • 6.3.1.1. Immunohistochemistry
    • 6.3.2. DNA Detection
      • 6.3.2.1. Polymerase Chain Reaction (PCR)
      • 6.3.2.2. Next-generation Sequencing (NGS)
      • 6.3.2.3. In Situ Hybridization
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Detection Technique

7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Biomarker, 2020 - 2034
    • 7.3.1. EGFR
    • 7.3.2. KRAS
    • 7.3.3. HER2
    • 7.3.4. BRAF V600E
    • 7.3.5. Others
    • 7.3.6. 7.4 Market Attractiveness, by Biomarker

8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 8.3.1. Breast Cancer
    • 8.3.2. Lung Cancer
    • 8.3.3. Colorectal Cancer
    • 8.3.4. Liver Cancer
    • 8.3.5. Melanoma
    • 8.3.6. Others
  • 8.4. Market Attractiveness, by Cancer Type

9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020 - 2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Diagnostic Labs
    • 9.3.4. Others
  • 9.4. Market Attractiveness, by End-user

10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020 - 2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 11.2.1. Protein Detection
      • 11.2.1.1. Immunohistochemistry
    • 11.2.2. DNA Detection
      • 11.2.2.1. Polymerase Chain Reaction (PCR)
      • 11.2.2.2. Next-generation Sequencing (NGS)
      • 11.2.2.3. In Situ Hybridization
    • 11.2.3. Others
  • 11.3. Market Attractiveness, by Detection Technique
  • 11.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 11.4.1. EGFR
    • 11.4.2. KRAS
    • 11.4.3. HER2
    • 11.4.4. BRAF V600E
    • 11.4.5. Others
  • 11.5. Market Attractiveness, by Biomarker
  • 11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 11.6.1. Breast Cancer
    • 11.6.2. Lung Cancer
    • 11.6.3. Colorectal Cancer
    • 11.6.4. Liver Cancer
    • 11.6.5. Melanoma
    • 11.6.6. Others
  • 11.7. Market Attractiveness, by Cancer Type
  • 11.8. Market Value Forecast, by End-user, 2020 - 2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Diagnostic Labs
    • 11.8.4. Others
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country, 2020 - 2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Detection Technique
    • 11.11.2. By Biomarker
    • 11.11.3. By Cancer Type
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 12.2.1. Protein Detection
      • 12.2.1.1. Immunohistochemistry
    • 12.2.2. DNA Detection
      • 12.2.2.1. Polymerase Chain Reaction (PCR)
      • 12.2.2.2. Next-generation Sequencing (NGS)
      • 12.2.2.3. In Situ Hybridization
    • 12.2.3. Others
  • 12.3. Market Attractiveness, by Detection Technique
  • 12.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 12.4.1. EGFR
    • 12.4.2. KRAS
    • 12.4.3. HER2
    • 12.4.4. BRAF V600E
    • 12.4.5. Others
  • 12.5. Market Attractiveness, by Biomarker
  • 12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 12.6.1. Breast Cancer
    • 12.6.2. Lung Cancer
    • 12.6.3. Colorectal Cancer
    • 12.6.4. Liver Cancer
    • 12.6.5. Melanoma
    • 12.6.6. Others
  • 12.7. Market Attractiveness, by Cancer Type
  • 12.8. Market Value Forecast, by End-user, 2020 - 2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Diagnostic Labs
    • 12.8.4. Others
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Detection Technique
    • 12.11.2. By Biomarker
    • 12.11.3. By Cancer Type
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 13.2.1. Protein Detection
      • 13.2.1.1. Immunohistochemistry
    • 13.2.2. DNA Detection
      • 13.2.2.1. Polymerase Chain Reaction (PCR)
      • 13.2.2.2. Next-generation Sequencing (NGS)
      • 13.2.2.3. In Situ Hybridization
    • 13.2.3. Others
  • 13.3. Market Attractiveness, by Detection Technique
  • 13.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 13.4.1. EGFR
    • 13.4.2. KRAS
    • 13.4.3. HER2
    • 13.4.4. BRAF V600E
    • 13.4.5. Others
  • 13.5. Market Attractiveness, by Biomarker
  • 13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 13.6.1. Breast Cancer
    • 13.6.2. Lung Cancer
    • 13.6.3. Colorectal Cancer
    • 13.6.4. Liver Cancer
    • 13.6.5. Melanoma
    • 13.6.6. Others
  • 13.7. Market Attractiveness, by Cancer Type
  • 13.8. Market Value Forecast, by End-user, 2020 - 2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Diagnostic Labs
    • 13.8.4. Others
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Detection Technique
    • 13.11.2. By Biomarker
    • 13.11.3. By Cancer Type
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 14.2.1. Protein Detection
      • 14.2.1.1. Immunohistochemistry
    • 14.2.2. DNA Detection
      • 14.2.2.1. Polymerase Chain Reaction (PCR)
      • 14.2.2.2. Next-generation Sequencing (NGS)
      • 14.2.2.3. In Situ Hybridization
    • 14.2.3. Others
  • 14.3. Market Attractiveness, by Detection Technique
  • 14.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 14.4.1. EGFR
    • 14.4.2. KRAS
    • 14.4.3. HER2
    • 14.4.4. BRAF V600E
    • 14.4.5. Others
  • 14.5. Market Attractiveness, by Biomarker
  • 14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 14.6.1. Breast Cancer
    • 14.6.2. Lung Cancer
    • 14.6.3. Colorectal Cancer
    • 14.6.4. Liver Cancer
    • 14.6.5. Melanoma
    • 14.6.6. Others
  • 14.7. Market Attractiveness, by Cancer Type
  • 14.8. Market Value Forecast, by End-user, 2020 - 2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Diagnostic Labs
    • 14.8.4. Others
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Detection Technique
    • 14.11.2. By Biomarker
    • 14.11.3. By Cancer Type
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 15.2.1. Protein Detection
      • 15.2.1.1. Immunohistochemistry
    • 15.2.2. DNA Detection
      • 15.2.2.1. Polymerase Chain Reaction (PCR)
      • 15.2.2.2. Next-generation Sequencing (NGS)
      • 15.2.2.3. In Situ Hybridization
    • 15.2.3. Others
  • 15.3. Market Attractiveness, by Detection Technique
  • 15.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 15.4.1. EGFR
    • 15.4.2. KRAS
    • 15.4.3. HER2
    • 15.4.4. BRAF V600E
    • 15.4.5. Others
  • 15.5. Market Attractiveness, by Biomarker
  • 15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 15.6.1. Breast Cancer
    • 15.6.2. Lung Cancer
    • 15.6.3. Colorectal Cancer
    • 15.6.4. Liver Cancer
    • 15.6.5. Melanoma
    • 15.6.6. Others
  • 15.7. Market Attractiveness, by Cancer Type
  • 15.8. Market Value Forecast, by End-user, 2020 - 2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Diagnostic Labs
    • 15.8.4. Others
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Detection Technique
    • 15.11.2. By Biomarker
    • 15.11.3. By Cancer Type
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Abbott
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. F. Hoffmann-LA Roche AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Genomic Health, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. QIAGEN
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Agilent Technologies, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. AGENDIA N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. bioMerieux SA
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Illumina, Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Siemens Healthineers
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Thermo Fisher Scientific Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. BioGenex
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034
  • Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034
  • Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

List of Figures

  • Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034
  • Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023
  • Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023
  • Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023
  • Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023
  • Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023
  • Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023
  • Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
  • Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
  • Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023
  • Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034
  • Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
  • Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
  • Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034
  • Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034
  • Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034
  • Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034
  • Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034